PITTSBURGH, Oct. 20,
2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a
global healthcare company, announced today that its President,
Rajiv Malik, will be retiring as an
executive of the Company effective April 1,
2024.
Malik is a nearly 40-year pharmaceutical industry veteran who
has been responsible for the day-to-day operations of Viatris since
its inception, overseeing the Company's commercial business units,
the Commercial Development, Medical, Information Technology and
Quality functions, as well as Research & Development and
Operations. His strategic vision and leadership played a key role
in successfully integrating Viatris' legacy companies, Mylan and
Upjohn, formerly a division of Pfizer Inc.
With a unique leadership profile that combines his scientific,
operational and commercial expertise, as well as his strong
financial acumen, Malik has been a powerful asset for the Company.
Prior to Viatris, Malik served as president of Mylan, which he
first joined in 2007 following the Company acquiring a controlling
stake in Matrix Laboratories Limited, where he served as chief
executive officer from 2005 to 2008.
Malik will continue to serve on the Viatris Board of
Directors.
Robert J. Coury, Executive
Chairman of Viatris, said, "There are not enough words to express
how much Rajiv Malik as both a
partner and a leader has meant to me, first at Mylan and now
Viatris. He is the rarest of individuals who possesses a truly
unique skillset. We could not have reached all of our successes to
date without him. Most especially, I have appreciated the impact he
has made on all of the employees of the Company and how much he
deeply cares for them. With my impending transition from the
Viatris board of directors in December, I am pleased that Rajiv has
agreed to remain on the board to ensure the continuity of his
experience and insight on the overall operations of the Company. On
behalf of myself and my fellow members of the Board of Directors, I
sincerely cannot thank him enough for his leadership and dedication
over these past 16 years, and the Board looks forward to his
continued service."
Scott A. Smith, CEO of Viatris,
said, "It has been a true privilege to get to know and to work
alongside Rajiv during this past year. His knowledge of the
industry and overall command and understanding of all aspects of
our business are truly extraordinary. He has the deep respect of
every member of the Viatris team, and I could not have asked for a
better partner during my onboarding at the Company. I am also
tremendously grateful that as we continue on our path to execute on
Phase 2 of our strategic plan in 2024, his immense skillset and
experience will remain accessible to me as I continue to build my
leadership team for the future."
Speaking about his retirement, Rajiv
Malik said, "My time as President of Mylan and now Viatris
has truly been nothing less than extraordinary as we worked to
build a global healthcare powerhouse with unmatched scale and
patient impact. This journey was led in large part by Robert J. Coury, who I want to personally thank
for his constant mentoring, support and leadership. Robert's
incredible vision, passion and unwavering dedication consistently
brings out the best in all of us.
Malik continued, "Most especially, I would like to thank the
many leaders, team members and the thousands of employees both past
and present at Mylan and Viatris whom I have had the honor to serve
with. I am profoundly aware that I would be nothing without having
had the benefit of their amazing talents and extraordinary
dedication. They are and will always be the true heart and backbone
of this organization. Whether through our achievement of multiple
first product approvals, fighting to overcome barriers to patient
access around the globe, or literally changing the world through
our unprecedented HIV/AIDS commitment, I could not be prouder of
all that we have accomplished together. With that said, I am
pleased to remain available to Scott as he continues to build out
his operational structure and also look forward to continuing to
support the long-term success of the Company as a member of the
board."
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely
positioned to bridge the traditional divide between generics and
brands, combining the best of both to more holistically address
healthcare needs globally. With a mission to empower people
worldwide to live healthier at every stage of life, we provide
access at scale. In 2022 alone, we supplied high-quality medicines
to approximately 1 billion patients around the world. With our
exceptionally extensive and diverse portfolio of medicines, a
one-of-a-kind global supply chain designed to reach more people
when and where they need them, and the scientific expertise to
address some of the world's most enduring health challenges, access
takes on deep meaning at Viatris. We have the ability to touch all
of life's moments, from birth to end of life, acute conditions to
chronic diseases. We are headquartered in the U.S., with
global centers in Pittsburgh,
Shanghai and Hyderabad, India. Learn more at
viatris.com and investor.viatris.com, and connect with us on
Twitter, LinkedIn, Instagram and YouTube.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rajiv-malik-to-retire-as-president-of-viatris-effective-april-1-2024-301963593.html
SOURCE Viatris Inc.